Shots:

• The P-II study involves assessing Olamkicept (300/600mg- q2w- IV) vs PBO in 91 patients in a ratio (1:1:1) who had active UC with a full Mayo score ≥5- a rectal bleeding subscore ≥1- an endoscopy subscore ≥2- and had an inadequate response with conventional UC therapy
• The study met its 1EPs & 2EPs- demonstrating higher clinical response rates after 12wks. of treatment with 600mg dose & more patients achieved clinical remission and mucosal healing respectively. Olamkicept was well tolerated with the acceptable safety profile
• Olamkicept is the only clinical stage selective IL-6 inhibitor that works through the trans-signaling mechanism

  Ref: PRNewswire | Image: i-Mab